Fig. 2From: Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS studyProportion of patients with ≥ 50% reduction in monthly migraine days from baseline during 12 weeks by age. CI, confidence interval; OR, odds ratio. aP < 0.001 vs placeboBack to article page